KeViRx

Spun out of the University of Pittsburgh and University of Virginia, KeViRx, Inc. focuses on the development of novel small molecule therapeutics. Our current lead candidate, KVX-053, is an allosteric PTP4A3 phosphatase inhibitor that has potent activity in cell-based models of ovarian cancer and acute respiratory disease. KVX-053 also displays anti tumor activity in in vivo models of ovarian cancer and acute myeloid leukemia.